Streetbeat News

Products Services

TEVA

Teva Pharmaceuticals presented new pharmacokinetic modeling data for UZEDY, an extended-release injectable suspension for schizophrenia, at SIRS 2024. The data offers insights into dosing conversions for switching from a long-acting injectable formulation of risperidone. Additional data from the Phase 3 RISE trial reinforces UZEDY's efficacy and safety. The ADVANCE study will provide real-world findings on long-acting injectable utilization from various stakeholders.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:14 am

BMY

Bristol Myers Squibb presented new interim long-term efficacy data from the EMERGENT-4 trial for KarXT in schizophrenia at the 2024 SIRS Congress, showing continued improvements in symptoms at 52 weeks, with over 75% of participants achieving more than 30% improvement.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:11 am

SHLT

SHL Telemedicine Ltd. (NASDAQ:SHLT) showcased its SmartHeart portable 12-lead ECG technology at the U.S. Army's Project Convergence – Capstone 4 (PC-C4), the largest field experiment to date. SmartHeart was used in various trauma care levels in the Mojave Desert, demonstrating its reliability and effectiveness in extreme conditions. This inclusion highlights SHL's technology as a significant innovation in military healthcare.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:04 am

AMRN

New analyses of the REDUCE-IT study by Amarin demonstrate that its drug VASCEPA/VAZKEPA benefits high-risk cardiovascular disease patient subgroups. This could potentially enhance the drug's market position and appeal to a broader patient base.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:04 am

EH

EHang has received a production certificate from the CAAC, enabling mass production of its EH216-S pilotless eVTOL aircraft. This regulatory approval marks a significant milestone for EHang, potentially accelerating its commercialization efforts and expanding its market presence.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:58 am

ARWR

Arrowhead Pharmaceuticals announced new Phase 2 data of Plozasiran, showing significant reductions in triglycerides and APOC3 in patients with severe hypertriglyceridemia. The company plans to initiate Phase 3 studies, SHASTA-3 and SHASTA-4.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:54 am

TSLA

Tesla Inc. has deployed its Full Self-Driving (FSD) software on approximately 2 million vehicles in the U.S. The software, part of Tesla's advanced driver assistance systems, has reached a milestone of one billion miles driven. CEO Elon Musk highlighted the importance of vehicle autonomy to Tesla's market value and mentioned the potential of licensing FSD to other automakers, despite no current agreements. The company aims to enhance FSD adoption with initiatives like a 30-day free trial.

Portfolio Pulse from Anan Ashraf

April 08, 2024 | 6:52 am

REGN

Regeneron Pharmaceuticals presented pivotal data on Linvoseltamab at AACR 2024, showing a high response rate in heavily pre-treated multiple myeloma patients. The study with 117 patients showed a 71% objective response rate, with significant percentages achieving complete responses or very good partial responses. The median duration of response, progression-free survival, and overall survival were not reached, indicating promising outcomes. Among patients with a complete response, 93% were minimum residual disease negative.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:37 am

ITOS

iTeos Therapeutics is set to present preclinical data on EOS-984 at AACR 2024, showcasing its potential to restore T cell activity from adenosine suppression. This development could mark a significant advancement in cancer treatment strategies.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:26 am

BDTX

Black Diamond Therapeutics presented novel real-world evidence at the 2024 AACR Annual Meeting, highlighting the evolving EGFR mutation landscape in NSCLC and the potential of BDTX-1535. Data showed 20-30% of EGFRm NSCLC patients have non-classical mutations, which can co-express with the L858R mutation, leading to shorter response to osimertinib. BDTX-1535 is positioned as the most advanced fourth-generation oral TKI targeting a broad spectrum of EGFR mutations, including classical, non-classical, and C797S resistance mutations.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 6:15 am